Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07150988
PHASE2

A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-09-26

Completion Date

2026-11-06

Last Updated

2025-09-02

Healthy Volunteers

No

Conditions

Interventions

DRUG

HSK44459 dose level 1

HSK44459 dose level 1 oral administration

DRUG

HSK44459 dose level 2

HSK44459 dose level 2 orally administration

DRUG

placebo

placebo oral adminisitration

Locations (1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China